New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
NCT ID NCT04833114
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 33 times
Summary
This Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond to initial treatment. The main goal was to see if the new combination improves event-free survival compared to R-ICE alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AKH Meduni Wien Universitätsklinik für Innere Medizin I:
Vienna, 1090, Austria
-
Belfast City Hospital
Belfast, BT9 7AB, United Kingdom
-
Clínica Universidad de Navarra (Madrid location)
Madrid, 28027, Spain
-
Clínica Universidad de Navarra (Pamplona location)
Pamplona, 31008, Spain
-
Complejo Asistencial Universitario de Salamanca
Salamanca, 37007, Spain
-
Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, 35012, Spain
-
Complejo Hospitalario Universitario de Vigo
Vigo, 36212, Spain
-
DIAKO Ev.Diakonie-Krankenhaus gemeinnützige GmbH
Bremen, Germany
-
Derriford Hospital, Plymouth
Plymouth, PL6 8DH, United Kingdom
-
Georg-August-Universität Göttingen Universitätsmedizin Göttingen
Göttingen, Germany
-
HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation
Berlin, 13125, Germany
-
Hanusch Krankenhaus
Vienna, 1140, Austria
-
Helios St. Johannes Klinik
Duisburg, Germany
-
Helios Universitätsklinikum Wuppertal
Wuppertal, Germany
-
Hospital Clinic i Provincial de Barcelona
Barcelona, 08036, Spain
-
Hospital Clínico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital General Universitario de Alicante
Alicante, 03010, Spain
-
Hospital Germans Trias I Pujol
Badalona, 08916, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 8035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundación Jimenez Díaz
Madrid, 28040, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, 39908, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Hospital Universitario Son Espases
Palma, Balearic Islands, 07120, Spain
-
Hospital Universitario Virgen de la Arrixaca
Murcia, 30003, Spain
-
Hospital Universitario Virgen del Rocío
Seville, 41013, Spain
-
Hospital Universitario de Cabueñes
Gijón, 33394, Spain
-
Hospital Universitario de Donostia
Donostia / San Sebastian, 20014, Spain
-
Institut Català d'oncologia de L'Hospitalet (ICO-L'Hospitalet)
L'Hospitalet de Llobregat, 08908, Spain
-
Kepler Universitätsklinikum Med Campus III, Univ.-Klinik für Hämatologie und Internistische Onkologie
Linz, 4021, Austria
-
Klinik für Onkologie, Hämatologie und Palliativmedizin
Düsseldorf, 40479, Germany
-
Klinikum Chemnitz gGmbH
Chemnitz, Germany
-
Klinikum Ludwigshafen
Ludwigshafen, Germany
-
Klinikum Mutterhaus
Trier, Germany
-
Klinikum Oldenburg
Oldenburg, Germany
-
Klinikum Stuttgart
Stuttgart, Germany
-
Klinikum Wels-Grieskirchen Abteilung für Innere Medizin IV
Wels, 4600, Austria
-
LKH Hochsteiermark Standort Leoben Abteilung für Innere Medizin Department für Hämato-Onkologie
Leoben, 8700, Austria
-
Landeskrankenhaus Salzburg
Salzburg, 5020, Austria
-
Nottingham City Hospital
Nottingham, NG5 1PB, United Kingdom
-
Ordensklinikum Linz GmbH- Elisabethinen: I. Interne Abteilung Hämato-Onkologie
Linz, 4020, Austria
-
Philipps-Universität Marburg
Marburg, Germany
-
Queens Hospital, Romford
Romford, RM7 0AG, United Kingdom
-
Royal Cornwall Hospital
Cornwell, TR1 3LJ, United Kingdom
-
St James University Hospital
Leeds, LS9 7TF, United Kingdom
-
St. Johannes Hospital Dortmund
Dortmund, Germany
-
Städtisches Klinikum Braunschweig
Braunschweig, Germany
-
Städtisches Krankenhaus Kiel
Kiel, Germany
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
UK Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie
Graz, 8036, Austria
-
University Hospital Southampton NHS
Southampton, S016 6YD, United Kingdom
-
University London College Hospitals
London, NW1 2PG, United Kingdom
-
Universitätsklinikum Dresden
Dresden, Germany
-
Universitätsklinikum Frankfurt
Frankfurt, Germany
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
-
Universitätsklinikum Jena
Jena, Germany
-
Universitätsklinikum Magdeburg
Magdeburg, Germany
-
Universitätsklinikum Münster
Münster, Germany
-
Universitätsklinikum RWTH-Aachen
Aachen, Germany
-
Universitätsklinikum Ulm
Ulm, Germany
-
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany
-
Unversitätsmedizin Rostock
Rostock, Germany
-
Westpfalz-Klinikum GmbH
Kaiserslautern, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Polatuzumab vedotin (a targeted antibody-drug conjugate) combined with rituximab, ifosfamide, carboplatin, and etoposide (chemotherapy)
What this could lead to
If successful, this combination could become a new standard salvage therapy for people with relapsed or refractory DLBCL, potentially improving the chance of remission before a stem cell transplant.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely published. Adding polatuzumab vedotin may increase side effects like nerve damage or infections, and it may not improve outcomes enough to change current practice.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.